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Abstract
Clinical trials rely on multidisciplinary teams for successful delivery. Pathologists should be involved in clinical
trial design from the outset to ensure that protocols are optimised to deliver maximum data collection and trans-
lational research opportunities. Clinical trials must be performed according to the principles of Good Clinical
Practice (GCP) and the trial sponsor has an obligation to ensure that all of the personnel involved in the trial
have undergone training relevant to their role. Pathologists who are involved in the delivery of clinical trials are
often required to undergo formal GCP training and may additionally undergo Good Clinical Laboratory Practice
training if they are involved in the laboratory analysis of trials samples. Further training can be provided via
trial-speciﬁc investigator meetings, which may be either multidisciplinary or discipline-speciﬁc events. Patholo-
gists should also ensure that they undertake External Quality Assurance schemes relevant to the area of diagnos-
tic practice required in the trial. The level of engagement of pathologists in academia and clinical trials research
has declined in the United Kingdom over recent years. This paper recommends the optimal training and accredi-
tation for pathologists undertaking clinical trials activities with the aim of facilitating increased engagement.
Clinical trials training should ideally be provided to all pathologists through centrally organised educational
events, with additional training provided to pathologists in training through local postgraduate teaching. Pathol-
ogists in training should also be strongly encouraged to undertake GCP training. It is hoped that these recom-
mendations will increase the number of pathologists who take part in clinical trials research in order to ensure a
high level and standard of data collection and to maximise the translational research opportunities.
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Introduction
Pathologists play an important role in the design and
delivery of clinical trials internationally, whether these
are to test the effectiveness of new devices or novel
treatments e.g. drugs or surgical procedures. Clinical
trial pathologists should be involved in trial design
from the outset to ensure that the collection of tissue
and/or morphological and molecular data for bio-
marker analysis/translational research is performed to
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a consistently high standard [1]. All too often clinical
trials are designed without the involvement of patholo-
gists leading to incomplete data collection, unworkable
protocols and lost translational research opportunities.
In our opinion, there is an urgent need to increase the
number of pathologists involved in clinical trial deliv-
ery, clinical trial design (through membership of trial
management groups) and clinical trial monitoring
(through membership of data monitoring committees
in order to improve the overall quality of clinical trials
research). We believe that pathologists should be
involved in clinical trials planning to some extent in
almost all trials to optimise the quality of pathological
endpoint generation and ensure that translational
opportunities are maximised.
Whilst it is recognised that there is ad hoc training
available for clinical trials pathologists from a variety
of sources, there is limited existing guidance as to the
minimum amount of training that is essential, or
indeed desirable, for them to undertake. This guidance
is not currently available from one unifying source.
Current sources of training often fail to take into
account the required level of engagement in a clinical
trial. Pathologist involvement in clinical trials should
be seen as a mainstream clinical activity and not
restricted to pathologists with formal academic
appointments. Pathologists will have a variable input
into the running and management of clinical trials,
with most pathologists providing ‘local’ input in their
centre e.g. collection of tissue, completion of pathol-
ogy case report forms etc. A more limited number of
pathologists will have more of a ‘central’ role includ-
ing chief investigator/central pathology lead with
responsibility for generating the protocol and design of
the pathological endpoints.
Over recent years there has been a signiﬁcant
decline in academic pathologists in the United King-
dom (UK) resulting in a low level of engagement in
clinical trials work [2]. In 2016 the National Cancer
Research Institute (NCRI) launched the Cellular
Molecular Pathology (CM-Path) initiative to address
this and a number of other issues in order to increase
engagement and capacity in both academic and molec-
ular pathology [3]. The Clinical Trials workstream of
CM-Path organised a 1 day workshop in March 2017,
one of the objectives of which was to determine the
optimal training and accreditation for pathologists tak-
ing part in clinical trials work within the UK, bringing
in expertise from all CM-Path workstreams. Other
topics considered during the workshop included regu-
lation and accreditation for laboratories taking part in
clinical trials, and optimal scoring and reporting of
clinical trial specimens to include digital pathology
and image analysis, which has been summarised in a
separate manuscript [4]. It was hoped that dissemina-
tion of this information would provide pathologists
with the knowledge to be able to get more involved in
clinical trials work, either as a local pathologist contrib-
uting to the collection of data, or as a central patholo-
gist with management responsibilities including
protocol design. The workshop formulated ‘practice
points’ to help pathologists navigate clinical trials train-
ing and accreditation and these are placed in italics at
the end of each section and compiled in Table 1.
In the UK, pathologist engagement can be increased
by ensuring that all of the NCRI clinical studies
groups have pathologist representation to facilitate
review of at least the national portfolio trials, encour-
aging new generations of early career pathologists to
be engaged with clinical trials research early in their
careers, and ensuring that pathologists have access to
funding to ‘buy out’ their time for research (a key
objective of the CM-Path clinical trials workstream).
Further review of all trials by the CM-Path Clinical
Trials Pathology Advisory Group (CT-PAG) prior to
funding applications is also to be encouraged.
The aim of the workshop was to evaluate the existing
training and accreditation guidance, along with current
sources of training, and to produce a consensus state-
ment that could act as a single source of guidance for
clinical trials pathologists, as well as directing them to
Table 1. Summary of clinical trials training and accreditation
practice points
• Basic GCP training, as a minimum, should be strongly encouraged for
all clinical staff who are involved in any aspect of clinical trial work.
The speciﬁc type of GCP training undertaken should be aligned to
cover the speciﬁc tasks that the researcher is expected to perform. As
a minimum all pathologists should understand the basics of clinical
trial governance. Additional training should be considered for
pathologists undertaking translational research in a central laboratory
e.g. GCLP training.
• In the UK, CM-Path should engage with the NIHR CRN to develop an
online GCP training resource speciﬁcally tailored to pathologists and
translational researchers involved in clinical trials research.
• GCLP training should be considered as an additional training resource
for all pathologists and laboratory staff who undertake translational
laboratory analysis of clinical trial samples.
• Trial-speciﬁc investigator meetings are an invaluable source of
information and training and are highly recommended during the
set-up of a trial.
• Pathologists should participate in specialist EQA schemes appropriate
to the ﬁeld of their clinical research involvement.
• Pathologists in training should be strongly encouraged to learn about
the role of pathologists in clinical trials and undertake further
training in this area where there is interest e.g. GCP training.
• All pathologists should have access to basic training in the main
concepts involved in clinical trials research through national
workshops.
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potential sources of further information. It was recog-
nised that there is an urgent need for such guidance, as
part of a move to assuring high quality pathology in
clinical trials, and to maximise the available transla-
tional research opportunities. The working group appre-
ciated the importance of achieving a balance between
assuring high quality pathology in clinical trials and not
imposing unrealistic demands that might deter potential
clinical trials pathologists from taking part.
Overview of current guidance
The Medicines and Healthcare Products Regulatory
Agency (MHRA) guidance on Good Clinical Practice
(GCP) quotes the Clinical Trials Regulations which
state that ‘No person shall conduct a clinical trial other
than in accordance with the conditions and principles of
good clinical practice’ and thus advises that all person-
nel involved in the analysis and evaluation of clinical
trial samples should receive GCP training ‘commensu-
rate with their roles and responsibilities.’ Although there
is no legal requirement to undergo formal GCP training,
such training is often considered to be mandatory by
clinical trials sponsors, who will usually ask all person-
nel involved in the trial (including named site patholo-
gists) to provide evidence of completion of training.
This training should ordinarily be refreshed every
2 years. Other pathologists who contribute to the deliv-
ery of the trial e.g. by reporting cases from enrolled
patients, are not usually mandated by sponsors to under-
take GCP training as they are technically acting under
the guidance of the named site pathologist. If the named
site pathologist will not personally deliver all of the
trial-related pathology in the centre, it is important that
they still retain oversight and communicate clearly the
requirements of the trial to the rest of their team. Labo-
ratory staff who are involved in the analysis of clinical
trial samples are often not expected to undertake GCP
training, although they may alternatively undertake
Good Clinical Laboratory Practice (GCLP) training to
ensure that they can perform their role according to the
principles of GCP. Ultimately, the type of training
required and who should undergo training is determined
by the clinical trial sponsor, who retains overall respon-
sibility for the delivery of the trial.
GCP training
GCP is an internationally agreed set of standards that
govern how clinical research is conducted to ensure
that the rights and safety of the participants are pro-
tected and that the research data are reliable. GCP
training is readily available and can be undertaken
either as a face-to-face exercise or via on-line training,
both of which should be made available free of charge
for clinical staff involved in clinical trials work. Some
organisations offer their own in-house training pro-
grammes. As an alternative, free on-line training is
easy to undertake at a convenient time and can be
accessed via the National Institute for Health Research
(NIHR) Clinical Research Network (CRN) [5]. There
are a number of different NIHR CRN courses avail-
able depending on the type and level of training
required, although currently none is speciﬁcally tai-
lored to pathologists or translational researchers. This
could be addressed by CM-Path working with the
NIHR CRN to develop a set of appropriate resources.
It is important that any training undertaken covers the
speciﬁc tasks the researcher will be expected to per-
form. On-line GCP training is not an onerous under-
taking and can usually be completed within
approximately 3 h. The training usually covers all of
the important aspects of clinical trials working includ-
ing the regulations for setting up and delivering clini-
cal trials, the roles and responsibilities of organisations
and individuals involved, required documentation,
consenting and safety.
Basic GCP training, as a minimum, should be strongly
encouraged for all clinical staff who are involved in
any aspect of clinical trial work. The speciﬁc type of
GCP training undertaken should be aligned to cover
the speciﬁc tasks that the researcher is expected to
perform. As a minimum all pathologists should under-
stand the basics of clinical trial governance. Addi-
tional training should be considered for pathologists
undertaking translational research in a central labo-
ratory e.g. GCLP training (see below).
In the UK, CM-Path should engage with the NIHR
CRN to develop an online GCP training resource spe-
ciﬁcally tailored to pathologists and translational
researchers involved in clinical trials research.
GCLP training
GCLP training essentially covers the regulation of the
laboratory analysis of clinical trials samples according
to the principles of GCP. Whilst GCLP standards are
comprehensive, they are not a recognised legal frame-
work unlike GCP. Despite this, GCLP training is
potentially very useful for laboratory staff involved in
clinical trial work and should be considered as an
additional training resource for pathologists who
undertake translational laboratory analysis of clinical
trial samples. Again this can be provided by on-line
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training [6], although this is not free of charge as far
as we are aware unlike the NIHR CRN GCP courses.
GCLP training should be considered as an additional
training resource for all pathologists and laboratory
staff who undertake translational laboratory analysis
of clinical trial samples.
Additional training and quality assurance
available
Trial-speciﬁc investigator meetings
Many clinical trials will hold trial-speciﬁc investigator
meetings, particularly at the start of a trial and possibly
at regular intervals during it. These meetings are an
opportunity for the trial management team to dissemi-
nate the plans for the conduct of the trial, and are a
very useful source of trial speciﬁc information for clin-
ical trials pathologists. They are also an opportunity
for pathologists to ask questions to clarify anything
that may not be clear in the protocol. Pathologists
should be recognised as crucial to the successful deliv-
ery of many clinical trials and essential to maximise
the translational research opportunities and should be
actively encouraged to attend by the wider multidisci-
plinary team. There are two main types of investigator
meeting:
1. Multidisciplinary investigator meetings – for all
trial investigators to attend.
2. Discipline-speciﬁc workshops – where investigators
from a single discipline attend to discuss the
discipline-speciﬁc requirements of the trial.
Both of these types of meeting are valuable for clin-
ical trials pathologists to attend, but pathology-speciﬁc
workshops are especially useful if pathologists are
involved in primary or secondary endpoint analysis,
particularly if these are obtained by non-routine
methods. Such workshops may contain a practical
discipline-speciﬁc training element, particularly if the
data to be collected are non-routine. Those of us with
personal experience (NPW) have found that
pathology-speciﬁc workshops are invaluable, both as a
source of information and as a potential venue for dis-
cussing issues and practical difﬁculties with ongoing
trial involvement. They are a useful forum for a two-
way dialogue between the central pathologists who
have written the protocol and the site pathologists who
carry out the trial to agree on the deliverability of the
protocol for pathology end point generation. Indeed it
is not unusual for protocols to be modiﬁed on the basis
of feedback from local pathologists who will perform
the day-to-day data collection.
Whilst face-to-face meetings are ideal, funding
needs to be obtained by the sponsor to meet the run-
ning costs and not all pathologists are likely to be able
to attend a single event meaning that multiple work-
shops may be required. Meetings can satisfactorily be
alternatively run as a web-based session (keeping time
and cost demands to a minimum) and/or can be
attended by one representative pathologist from each
site (who can then distribute the information to other
pathologists in their local team), and this should be
covered by the pathology support funding for the trial.
An additional beneﬁt of attendance at trial-speciﬁc
investigator meetings is that Continuing Professional
Development (CPD) points are often allocated for
attendance, thus providing an additional incentive for
pathologists to attend.
Trial-speciﬁc investigator meetings are an invaluable
source of information and training and are highly
recommended during the set-up of a trial.
Specialist EQA schemes
It is important that clinical trials pathologists partici-
pate in an External Quality Assurance (EQA) scheme
relevant to the ﬁeld of their clinical research involve-
ment e.g. a pathologist involved in colorectal cancer
trials would be expected to subscribe to the national
gastrointestinal EQA scheme. This helps to ensure a
high level of quality in that diagnostic ﬁeld, as well as
providing demonstrable competence in the form of a
certiﬁcate of participation for MHRA inspections.
However, it is recognised that for some specialist areas
of work, appropriate EQA schemes do not exist or are
oversubscribed. In trials where molecular testing is
performed within pathology laboratories, it is impor-
tant that laboratories subscribe to the relevant molecu-
lar EQA schemes where these are available.
Pathologists should participate in specialist EQA
schemes appropriate to the ﬁeld of their clinical
research involvement.
Training for the future
Any pathologist with an interest in clinical trials
should be familiar with the generic governance of clin-
ical trials as well as concepts such as biobanking and
biomarker validation etc according to the requirements
of the trial(s) they are involved in. Speciﬁc items of
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governance that are often poorly understood by pathol-
ogists include the limitations of contracts, particularly
in commercial trials, that can impact on the ability to
publish the result. Speciﬁc training in clinical trial con-
tract issues e.g. non-disclosure, intellectual property
etc would be very useful to understand potential con-
ﬂicts of interest at an early stage of trial design.
Whilst a central clinical trial pathologist might be
expected to have in-depth knowledge of the whole of
the trial process, it is probably not necessary or feasible
for every collaborating local trial pathologist to demon-
strate such expertise. In general, central trial pathologists
who sit on the trial management group and are involved
in writing the protocol/analysis should be expected to
have a greater level of training; however, currently, there
is no formal platform in which training in these areas
can easily be delivered. However, we believe that all
pathologists should have a basic knowledge of clinical
trials research given the large number of clinical trials
being delivered across the health service including in
many small district general hospitals. Various concepts
for the provision of basic training necessary for clinical
trials pathologists have been considered.
Involving pathologists in training
The UK Royal College of Pathologists (RCPath) His-
topathology curriculum requires that all pathologists in
training have the appropriate knowledge, skills and
behaviours to undertake research on completion of
training [7]. There is no speciﬁc mention of training in
clinical trials research. The working group agreed that
an element of basic clinical trials training should be
provided within this framework, and would be best
achieved by integration into local Fellowship of the
Royal College of Pathologists (FRCPath) training pro-
grammes. In addition, speciﬁc training modules could
be developed nationally through CM-Path for clinical
trials pathologists. It was also agreed that the RCPath
curriculum could speciﬁcally state that pathologists in
training should have a basic knowledge of the con-
cepts surrounding pathology involvement in clinical
trials. CM-Path will continue to work with the RCPath
to ensure that this is recognised.
One other source of training for pathologists in
training that could easily be provided without addi-
tional funding would be the requirement to undertake
GCP training in stage B of FRCPath training. Potential
beneﬁts of providing basic clinical trials training to
pathologists in training include:
• Early exposure of pathologists to clinical trial work,
which could help to address the current shortage of
pathologists willing to get involved in the develop-
ment and delivery of trials.
• Increased awareness of the beneﬁts of clinical trials,
both for patients and for the future development of
pathology.
• Opening up possibilities for the negotiation of clini-
cal trials involvement as part of new consultant/staff
pathologist job plans.
• Ensuring that pathologists in training meet the
requirements of the current Histopathology curricu-
lum in terms of the expected knowledge, skills and
behaviours around research.
It was recognised that incorporating compulsory
GCP training into an already packed training pro-
gramme might be unrealistic; however, it is not cur-
rently clear whether speciﬁc research training is
provided across all training programmes in the UK
and where it is provided, how this is delivered. As a
minimum, the working group felt that pathologists in
training should be strongly encouraged to undertake
GCP training, directing pathologists in training to
suitable, easily accessible, free training modalities
e.g. on-line training available through the NIHR CRN.
Teaching the basic concepts of research should already
be delivered to meet the curriculum requirements, and
training programmes should be encouraged to speciﬁ-
cally cover the basics of clinical trials work during
their regional teaching programmes or as part of a cen-
trally organised teaching event. In addition it may be
possible to work with medical schools to deliver man-
datory GCP training during undergraduate courses so
that medical graduates have a clear understanding of
the roles and responsibilities of clinicians involved in
clinical trials research.
Pathologists in training should be strongly encour-
aged to learn about the role of pathologists in clinical
trials and undertake further training in this area
where there is interest e.g. GCP training. CM-Path
will continue to work with the RCPath to ensure that
the curriculum recognises the importance of training
in the principles of clinical trials research.
It is important that pathologists in training recognise
the collective and individual value of taking part in
clinical trials research. Beyond the beneﬁts in terms of
the advancement of medical knowledge, pathologists
who engage in clinical trials activity will ﬁnd several
opportunities to improve their curriculum vitae
through peer reviewed publications (often in high
impact factor journals), attendance at investigator
meetings, a deeper understanding of clinical trials
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design/governance and learning new specialist areas of
pathology. With commercial trials activity, there is
also the opportunity to obtain consultancy fees either
for personal gain or to contribute towards departmental
research funds.
Whilst training in the optimal collection of tissue/-
data and clinical trial governance is important, it is
also critical that all pathologists in training are trained
as competent ‘morpho-molecular’ diagnostic patholo-
gists [8,9], in order to support the stratiﬁed allocation
of patients into national prospective randomised clini-
cal trials e.g. MRC FOCUS4 [10] and the CRUK
National Lung Matrix Trial [11]. It is also of funda-
mental importance that we train a signiﬁcant subset of
pathologists as effective clinical/translational
researchers to play a major role in the design of new
trials and undertake retrospective exploratory and vali-
datory biomarker analyses on clinical trial samples.
Senior pathologists engaged in clinical trials
research should be strongly encouraged to consider
succession planning by engaging junior consultant/-
staff pathologist colleagues or pathologists in train-
ing as deputies in order to provide ‘on the job’
training. They should be recognised as formal depu-
ties on the trial delegation log and must ensure that
the basic training requirements have been met
i.e. GCP training.
Central workshops for training
It was recognised that whilst it is relatively easy to
provide clinical trial training to pathologists in training
through FRCPath teaching events and changes to the
curriculum, it is more difﬁcult to provide training to
established consultants/staff pathologists. One poten-
tial solution is the organisation of central workshops,
which would be open to both pathologists in training
and current consultants/staff pathologists and would
attract CPD points for participation. To date CM-Path
has already held two such events to stimulate interest
and involvement in clinical trials research from pathol-
ogists at all stages of their career.
All pathologists should have access to basic training
in the main concepts involved in clinical trials
research through national workshops.
A summary of potential training opportunities is
provided in Table 2.
Conclusion
Pathologists are vital to the successful delivery of clin-
ical trials, and should be involved in the design and
Table 2. Summary of the clinical trials training opportunities for pathologists discussed at the CM-Path workshop with guidance on
when to consider the various activities
Training activity When should this training activity be considered?
Good Clinical Practice (GCP)
training
All pathologists who undertake clinical trials work should be strongly encouraged to undertake GCP training as
a minimum – clinical trial sponsors usually insist on collecting documentary evidence of GCP training for
pathologists who are listed on the site delegation log. Pathologists in training should consider undertaking
GCP training at an early stage to understand the basics of clinical trials governance. Local training
programmes could consider recommending this – at an appropriate stage of training and pathologists who
are actively engaged in clinical trials should recommend this training to their junior staff.
Good Clinical Laboratory Practice
(GCLP) training
GCLP training covers the elements of GCP that are relevant to laboratory practice. This should be considered in
addition to basic GCP training for pathologists who are involved in laboratory translational research and also
should be undertaken by laboratory scientists and technicians dealing with clinical trials samples.
Multidisciplinary trial investigator
meetings
Helpful for the lead pathologist from each site to attend to understand the wider context of the trial and
maximise translational research opportunities. These meetings may be used to disseminate the results at the
end of the trial. The lead pathologist can feed back to local colleagues who will assist in trial delivery.
Pathology speciﬁc trial investigator
meetings
Very useful to discuss the practical issues of protocol delivery, especially the deliverability of pathological
endpoints.
Specialist EQA schemes Where relevant specialist clinical reporting schemes exist, pathologists should subscribe to schemes relevant to
the clinical area of interest. Where molecular testing forms part of the trial, the relevant EQA schemes should
be undertaken where these are available (https://www.ukneqas-molgen.org.uk/).
FRCPath training programmes Postgraduate pathology training programmes should consider inviting pathologists engaged in clinical trials
activity to present the basics of clinical trials research and give some examples of how best to get involved.
Deputising for senior clinical trials
pathologists
Pathologists in training or consultants/staff pathologists with no/limited trials experience should consider
deputising for senior clinical trials pathologists to begin to develop some experience within a supportive
environment. This will assist senior trials pathologists with succession planning.
Central workshops Pathologists in training and consultant/staff pathologists should consider attending central workshops e.g. those
organised by CM-Path, covering the basics of clinical trials research with tips on how to get involved.
105Training and accreditation for trials pathologists
© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res; April 2019; 5: 100–107
delivery of all trials to ensure maximum data collec-
tion and translational opportunities. There are few
mandatory training requirements beyond GCP training,
but other sources of education include GCLP training,
trial-speciﬁc investigator meetings, specialist EQA
schemes, dedicated sessions during local postgraduate
teaching, and centrally organised events. In the UK,
CM-Path will continue to work with the RCPath to
ensure that the curriculum recognises the importance
of training in clinical trials research to ensure that we
create a generation of pathologists with an interest in
and the skills required to deliver successful clinical tri-
als with quality assured pathology support and maxi-
mal translational research opportunities.
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